- Home
- GAN vs SKYE Comparison
GAN vs SKYE Comparison
Compare GAN & SKYE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GAN
- SKYE
- Stock Information
- Founded
- GAN 1999
- SKYE 2012
- Country
- GAN United States
- SKYE United States
- Employees
- GAN N/A
- SKYE N/A
- Industry
- GAN Computer Software: Programming Data Processing
- SKYE Biotechnology: Pharmaceutical Preparations
- Sector
- GAN Technology
- SKYE Health Care
- Exchange
- GAN Nasdaq
- SKYE Nasdaq
- Market Cap
- GAN 83.2M
- SKYE 80.7M
- IPO Year
- GAN 2020
- SKYE N/A
- Fundamental
- Price
- GAN $1.75
- SKYE $2.98
- Analyst Decision
- GAN
- SKYE Buy
- Analyst Count
- GAN 0
- SKYE 6
- Target Price
- GAN N/A
- SKYE $18.67
- AVG Volume (30 Days)
- GAN 280.3K
- SKYE 226.0K
- Earning Date
- GAN 03-12-2025
- SKYE 03-07-2025
- Dividend Yield
- GAN N/A
- SKYE N/A
- EPS Growth
- GAN N/A
- SKYE N/A
- EPS
- GAN N/A
- SKYE N/A
- Revenue
- GAN $134,024,000.00
- SKYE N/A
- Revenue This Year
- GAN $12.70
- SKYE N/A
- Revenue Next Year
- GAN $10.67
- SKYE N/A
- P/E Ratio
- GAN N/A
- SKYE N/A
- Revenue Growth
- GAN N/A
- SKYE N/A
- 52 Week Low
- GAN $1.17
- SKYE $2.31
- 52 Week High
- GAN $1.90
- SKYE $19.41
- Technical
- Relative Strength Index (RSI)
- GAN 37.00
- SKYE 48.34
- Support Level
- GAN $1.73
- SKYE $2.97
- Resistance Level
- GAN $1.78
- SKYE $3.31
- Average True Range (ATR)
- GAN 0.04
- SKYE 0.37
- MACD
- GAN -0.01
- SKYE 0.01
- Stochastic Oscillator
- GAN 18.75
- SKYE 40.00
About GAN GAN Limited
GAN Ltd provides Software-as-a-Service solutions for online casino gaming and sports betting applications. The company has two operating segments B2B and B2C. The B2B segment develops, markets, and sells instances of GameSTACK, GAN Sports, and iSight Back Office technology that incorporates comprehensive player registration, account funding, and back-office accounting and management tools that enable the casino operators to efficiently, confidently, and effectively extend their presence online in places that have permitted online real money gaming, and The B2C segment, which includes the operations of Coolbet, develops and operates a B2C online sports betting and casino platform that is accessible through its website in markets across Northern Europe, Latin America, and Canada.
About SKYE Skye Bioscience Inc. Common Stock
Skye Bioscience Inc is a pre-clinical pharmaceutical company located in San Diego, California. The company's clinical assets focus on the modulation of cannabinoid receptor 1 ("CB1") to provide novel treatments and alternatives for diseases caused by metabolic disorders, inflammation, fibrosis and neurodegeneration, such as obesity and glaucoma. The company's Phase 2 clinical candidates include nimacimab, a negative allosteric modulating antibody that inhibits peripheral CB1 receptors, currently being developed for the treatment of obesity and SBI-100 Ophthalmic Emulsion ("SBI-100 OE"), a CB1 agonist (activator), currently being developed for the treatment of glaucoma and ocular hypertension.